The price-to-earnings ratio for CVS Health Corp (NYSE: CVS) is 15.30x, which is above its average ratio. Moreover, the 36-month beta value for CVS is 0.55. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 8 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for CVS is 1.26B and currently, short sellers hold a 1.26% of that float. On June 02, 2025, CVS’s average trading volume was 10.28M shares.
CVS) stock’s latest price update
The stock price of CVS Health Corp (NYSE: CVS) has surged by 2.01 when compared to previous closing price of 62.78, but the company has seen a 6.34% gain in its stock price over the last five trading sessions. forbes.com reported 2025-05-29 that CVS Health Thursday sued the state of Arkansas, trying to thwart a law the healthcare company said would lead to the closure of all 23 CVS drugstores in the state.
CVS’s Market Performance
CVS Health Corp (CVS) has seen a 6.34% rise in stock performance for the week, with a -4.00% decline in the past month and a -2.56% plunge in the past quarter. The volatility ratio for the week is 0.71%, and the volatility levels for the past 30 days are at 2.41% for CVS. The simple moving average for the last 20 days is 0.77% for CVS stock, with a simple moving average of 7.63% for the last 200 days.
Analysts’ Opinion of CVS
Many brokerage firms have already submitted their reports for CVS stocks, with Leerink Partners repeating the rating for CVS by listing it as a “Outperform.” The predicted price for CVS in the upcoming period, according to Leerink Partners is $75 based on the research report published on February 13, 2025 of the current year 2025.
CVS Trading at -2.54% from the 50-Day Moving Average
After a stumble in the market that brought CVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.68% of loss for the given period.
Volatility was left at 2.41%, however, over the last 30 days, the volatility rate increased by 0.71%, as shares sank -7.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.70% lower at present.
During the last 5 trading sessions, CVS rose by +6.34%, which changed the moving average for the period of 200-days by +14.75% in comparison to the 20-day moving average, which settled at $63.55. In addition, CVS Health Corp saw 42.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVS starting from ROBBINS LARRY, who sale 2,276,068 shares at the price of $67.86 back on May 02 ’25. After this action, ROBBINS LARRY now owns 9,670,731 shares of CVS Health Corp, valued at $154,444,758 using the latest closing price.
ROBBINS LARRY, the Director of CVS Health Corp, sale 1,323,932 shares at $67.41 during a trade that took place back on May 05 ’25, which means that ROBBINS LARRY is holding 8,346,799 shares at $89,249,945 based on the most recent closing price.
Stock Fundamentals for CVS
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.14 for the gross margin
The net margin for CVS Health Corp stands at 0.01. The total capital return value is set at 0.06. Equity return is now at value 7.00, with 2.09 for asset returns.
Based on CVS Health Corp (CVS), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 1.06. The interest coverage ratio of the stock is 3.18.
Currently, EBITDA for the company is 13.68 billion with net debt to EBITDA at 4.8. When we switch over and look at the enterprise to sales, we see a ratio of 0.4. The receivables turnover for the company is 9.56for trailing twelve months and the total asset turnover is 1.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
To wrap up, the performance of CVS Health Corp (CVS) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
